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Abstract  
Mesenchymal cells transdifferentiation and
extracellular matrix deposition are involved in
the fibrotic process of Crohn’s disease (CD).
Mesenchymal smooth muscle cells (SMCs) de-
differentiation, driven by Platelet-derived
growth factor (PDGF) that counteracts
Transforming growth factor (TGF-β) has been
studied in vascular muscle. The role of SMCs in
intestinal fibrogenesis is still not clearly eluci-
dated. Aim of the study was to evaluate the pos-
sible myogenic contribution to CD fibrotic
process through the comparative analysis of
histological, morphometric and molecular alter-
ations occurring in human smooth muscle. Full
thickness specimens were obtained from CD
(non-involved and stenotic tracts) and healthy
(control) ileum. Tissues were processed for his-
tological and immunohistochemical (IHC)
analyses and SMCs were isolated from the mus-
cularis propria for morphofunctional and molec-
ular (qPCR) analyses. CD stenotic ileum
showed a significant increased thickness of all
layers compared to CD non-involved and control
ileum. IHC revealed an overexpression of a-
smooth muscle actin and collagens I-III
throughout all intestinal layers only in stenotic
tracts. The two growth factors, PDGF and TGF-β,
showed a progressive increase in expression in
the muscle layer from CD non-involved to
stenotic tracts. Freshly isolated SMCs presented
alterations in CD non-involved tracts that pro-
gressively increased in the stenotic tracts con-
sisting in a statistical increase in mRNA encod-
ing for PDGF-β and collagen III, paralleled to a
decrease in TGF-β and Tribbles-like protein-3
mRNA, and altered morphofunctional parame-
ters consisting in progressive decreases in cell
length and contraction to acetylcholine. These
findings indicate that intrinsic myogenic alter-
ations occur in CD ileum, that they likely pre-
cede stricture formation, and might represent
suitable new targets for anti-fibrotic interven-
tions.
Introduction
The Crohn’s disease (CD) is a chronic
relapsing inflammatory bowel disease poten-
tially affecting any portion of the gastrointesti-
nal tract characterized by a discontinuous and
ulcerous transmural inflammation often
involving the ileocecal region. Clinical CD
behavior is variable with more than one-third
of patients developing, in their lifetime, a
stricturing pattern, mainly associated to an
ileal location of the disease.1 The presence of
strictures may determine clinical intestinal
obstructions that usually need surgery and are
accompanied by high recurrence rates.2,3 While
the pathogenesis of inflammation in CD has
been extensively investigated, knowledge of
stricture pathogenesis still remains limited.
Fibrogenesis in CD has a complex etiology
resulting from a complicated interaction
among local inflammatory cells, cytokines and
mesenchymal intestinal cells (fibroblasts,
myofibroblasts and smooth muscle cells).4
Strictures are the result of chronic transmural
inflammation and they are due to an excessive
and abnormal deposition of extracellular
matrix produced by activated myofibroblasts,
that exhibit an hybrid phenotype between
fibroblasts and smooth muscle cells (SMCs).5-8
In CD, a state of constant differentiation and
de-differentiation among the three mesenchy-
mal phenotypes has been observed with a
prevalent phenotypic switch of fibroblasts into
myofibroblasts.9,10 The contribution of SMCs,
myofibroblast precursors,11 in CD fibrotic
process has been suggested but less extensive-
ly studied.12 In atheromatous fibrotic plaque
evolution,11 the main constituent is the SMC
that contributes to extracellular matrix (ECM)
components, throughout a process known as
phenotypic modulation, consisting in the tran-
sition from a quiescent, contractile phenotype
to a myofibroblast-like proliferative synthetic
state.13 In vascular muscle, the contractile phe-
notype is under control of transforming growth
factor beta (TGF-β) that, in association with
bone morphogenetic protein (BMP), inhibits
SMCs proliferation and migration, and stimu-
lates gene expression of the contractile
smooth-muscle protein a-actin.14-16 The switch
from a contractile to a synthetic SMCs pheno-
type is conversely driven by the Platelet-
derived growth factor beta (PDGF-β), that
counteracts TGF-β signaling by increasing
miR-24 expression, which induces a downreg-
ulation of the Tribbles-like protein-3 (Trb3)
and a decrease in Smad protein levels, key
molecules for TGF-β signaling.13,16 During tran-
sition to the synthetic phenotype, SMCs begin
to synthesize collagen.17
The aim of the present study was to evaluate
the possible contribution of intestinal human
smooth muscle to CD fibrotic process through
the comparative analysis of histological, mor-
phometric and molecular alterations occurring
in smooth muscle of non-involved and stenotic
ileum of patients with Crohn’s disease in
respect to control. 
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Materials and MethodsTissues specimens
Full thickness intestinal wall specimens
were obtained  from 9 patients (5 males and 4
females, median age 45, range 31-64 years, all
B2-L1 according to the Montreal classification)
subjected to surgery for CD obstructive symp-
toms. From each surgical specimen, two tissue
samples were collected from the diseased
stenotic tract and two from the macroscopically
non-involved bowel (CD non-involved tract),
proximal to the surgical margin of the resec-
tion. Control specimens of terminal ileum
were obtained from 3 patients, which had sur-
gery  for carcinomas of the right colon. Tissue
samples were collected from the resection mar-
gin, at least 5 cm from the neoplastic area,
immediately after surgical removal of the
tumor. Samples for primary SMCs culture were
immediately immersed in chilled antibiotics-
supplemented PBS buffer.Histology and morphometry
Samples were fixed in 10% buffered forma-
lin and embedded in low-paraffin. Three μm
sections were stained with hematoxylin-eosin
and Masson’s trichrome and observed under
an Olympus BX51 Light Microscope (Olympus,
Optical Co. Ltd, Tokyo, Japan). The degree of
intestinal inflammation was assessed and
scored on a 0-3 scale, as follows: 0, absence of
infiltrate; 1, infiltrate at the subepithelium and
lamina propria level; 2, infiltrate reaching
muscularis mucosae; 3, severe and extended
infiltrate reaching submucosa and/or involving
muscularis propria.18
The thickness of mucosa, submucosa, mus-
cularis propria and serosa layers of non-
involved and stenotic tracts was quantitatively
estimated. Two pathologists independently
performed histological score and morphomet-
ric analysis on all specimens. For each speci-
men more than 6 different sections were per-
formed and 6 random different fields for each
section  were analyzed in a double blind fash-
ion with an agreement always higher than
90%. Quantitative morphometric analysis of
the myenteric plexus area was also performed
and expressed as the area occupied by myen-
teric plexus/total area x 100. For each sample,
more than five myenteric plexuses positive for
neuronal cocktail (see below) were studied.
Data are expressed as the percentage of
immunohistochemical positive cells over the
total area examined.   Microphotographs were
taken by Olympus BX-51 (Optical Co. Ltd.) with
a videocam (Spot Insight, Diagnostic
Instrument, Inc., Sterling Heights, MI, USA)
and processed with an image analysis system
(IAS-Delta Sistemi, Rome, Italy) software.
Immunohistochemistry
For immunohistochemistry (IHC), sections
were mounted on glass slides coated with 0.1%
poly-L-lysine. After deparaffination, endoge-
nous peroxidase activity was blocked by a 20-
min incubation in hydrogen peroxide (2.5%).
Sections were incubated overnight at 4°C with
polyclonal antibodies to Transforming growth
factor beta (TGF-β1 #sc-146, 1:400), collagen
types I-III (#sc-8784 and #sc-8781 respectively,
1:200), Platelet-derived growth factor (PDGF-A
#sc-128, 1:100), C-kit (#sc-168, 1:400), a-
smooth muscle actin (a-SMA, #sc-32251,
1:400), a neuronal cocktail antibodies (S100,
#sc-7849-R; antineurofilament n-4142, Sigma
Aldrich, St. Louis, MO, USA; NSE #sc-292097,
1:2000) and Glial fibrillary acidic protein (GFAP
Sigma Aldrich G-3893, 1:400). Samples were
then rinsed with PBS for 5 min and incubated
with a labeled streptavidin-biotin-peroxidase
conjugate kit (Dako LSAB, cod. K0675, Dako-
Cytomation, Milan, Italy). After rinsing in PBS
for 10 min, the sections were incubated with
3,3-diaminobenzidine-tetrahydrochloride
(DAB, Sigma Aldrich) for 1-3 min. 
To demonstrate the specificity of immunore-
action, negative and positive controls were per-
formed for all immunoreactions. For negative
controls, the primary antibody was replaced
(same dilution) with normal serum from the
same species. For positive controls, the follow-
ing tissues were tested: mouse uterus extract,
human colon carcinoma and human breast can-
cer were used for TGFβ1, PDGF and C-kit
respectively, while a-SMA, collagen I and  III
and cocktail neuronal positivity are intrinsic in
the sample. Finally, the samples were counter-
stained with Mayer’s hematoxylin and observed
under a photomicroscope (Olympus BX51 Light
Microscopy). The intensity of the immunoreac-
tion was assessed and scored  according to the
density and extent of immunopositivity as fol-
lows: absent, no discernible staining; mild, lim-
ited to typical sides; moderate, marked positive
immunostaining in typical sides with a weak
positivity in atypical layers; and severe, strong
and transmural overexpression.19Colorimetric evaluation of collagencontent
Sections of 15-mm thick, 100 mm2 large,
were obtained from each specimen and used
for colorimetric evaluation. For this purpose
the sections were deparaffinized through suc-
cessive baths in absolute toluol,
toluol:ethanol (50:50) and 50% aqueous
ethanol and water. Staining procedures with
fast green FCF 0.1 (Chroma-Gesellschaft, no.
IA30, Stuttgart, Germany) and Sirius Red F3B
0.01% (Atomergic Chemical Corporation, no.
10022; Plainview, New York, NY, USA) were
performed according to Gascon-Barrè.20
Colors were eluted in 0.05 M NaOH and 50%
aqueous methanol. The eluted colors were
examined in a Lambda 4 B PE spectropho-
tometer. Correlations between absorbance
and protein estimations were assessed using
the following formulas according to Gascon-
Barrè:20
i) Non-collagenous protein determination
by: non-collagenous protein (mg) =
absorbance at 605 nm/2.08;
ii) Collagenous protein determination
using the latter interference factor by: col-
lagen (µg) = (absorbance at 540 nm- 0.26
absorbance at 605 nm)/38.4;
iii) Collagen content (collagen/protein
ratio) by: collagen content (µg/mg total pro-
tein) = µg collagen/(µg collagen+mg non-
collagenous protein)Primary culture of human intestin-al smooth muscle cells  
Human SMCs were isolated as previously
described.21 Briefly, slices of circular muscle
layer were incubated overnight in DMEM sup-
plemented with penicillin-streptomycin solu-
tion (10,000 U/mL), gentamicin (1 mg/mL),
anphotericin B (250 μg/mL), fetal bovine
serum, an ATP-regenerating system (ATP 3
mM, phosphocreatine 10 mM, creatine phos-
phokinase 10 U/mL), antimycin (10 μM) and
collagenase (150 U/mL). On the following day,
digested muscle strips were suspended in
DMEM supplemented only with FBS and
antibiotics for 20 min to allow spontaneous
dissociation of SMCs. Cells were then har-
vested and used immediately to prepare RNA
or to perform morpho-functional analysis. Total RNA extraction
Total RNA was harvested from human
SMCs using Trizol (Invitrogen-Life
Technologies, Paisley, UK), according to the
manufacturer’s protocol. RNA integrity was
confirmed by electrophoresis on 1% agarose
gel and ethidium bromide staining (0.1
μg/mL). RNA quantification was performed
using spectrophotometry, with optical density
at 260 nm used to estimate the concentration
of total RNA.  cDNA synthesis
Approximately 1 μg of total RNA, from each
preparation, was used for cDNA synthesis in a
total volume of 20 μL of RT-buffer using the
SuperSriptTM system (Invitrogen Life
Technologies) containing 50 mM Tris-HCl (pH
8.3), 75 mM KCl, 5 mM MgCl2, 10 mM dithio-
threitol (DTT), 0.5 mM deoxynucleoside
triphosphates (dNTP), 0.5 μg Oligo (dT) and
50 U of RT. The reactions were carried out at
42°C for 50 min and terminated by heating at
70°C for 15 min. 
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Real-time PCR
After treatment at 37°C for 30 min with 20-
50 units of RNase-free DNase I, oligo-dT
primers (Roche Diagnostics Corp.
Indianapolis USA) were used to synthesize
single-stranded cDNA. mRNAs were quanti-
fied using SYBR green Master Mix (Applera
Corp., Foster City, CA, USA) with specific
human oligonucleotides in a GeneAmp
Abiprism 7000 (Applera Corp.). In each assay,
calibrated and no-template controls were
included. Each sample was run in duplicate.
SYBR green dye intensity was analyzed using
the Abiprism 7000 SDS software (Applera
Corp.). All results were normalized to the
unaffected housekeeping gene β-actin. The
following specific human oligonucleotides
were used: PDGF-β: 5’-CGATCCGCTCCTTTG
ATGAT-3’; 5’-AGG CTGGTGTCCAAAGAATCC-3’;
TGF-β: 5’-AAAATCGAGCAAGCTATGGATCTAG-
3’, 5’-TGCTCTTTGAGGACCTCCACTT-3’; Trb3:
5’-CCTCTACGCCTTTTTCACT-3’; 5’-AGTATCT
CAGGTCCCACGTA-3’; Collagen III: 5’-GGGAA-
CAACTTGATGGTGCT-3’, 5’-CCTCCTTCAACAG
CTTCCTG -3’.Measurement of contractileresponse
Biological morpho-functional SMCs fea-
tures (cell length and contractile response)
were measured by image scanning microme-
try using a ProgRes® camera with CapturePro
2.6 application software  (Jenoptik Laser
Optik, Jena, Germany) installed on a phase-
contrast microscope Leica 2500 (Leica
Microsystems, Wetzlar, Germany), as
described previously.22 Quantitative evalua-
tion was carried out, in the control state and
upon exposure to a maximal dose of acetyl-
choline (1 µM), by measuring the length of 50
cells in sequential microscopic fields.
Contraction was expressed as percentage
decrease in cell length from control taken as
100.Data and statistical analysis  
Results are expressed as means±SE of trip-
licate examinations of n experiments, n refer-
ring to the number of experiments on speci-
mens derived from separate intestinal speci-
mens or primary cultures. Statistical analysis
was performed by parametric ANOVA test, cor-
rected for multiple comparisons by the
Bonferroni procedure. P values of less than
0.05 were considered significant.Ethical requirements 
The study was approved by the Ethical
Committee of La Sapienza University of Rome
(ref. no. 1106, 2010). All subjects gave
informed consent to the work.
Results
A significant increased thickness of all wall
layers, except serosa, was observed  in  CD
stenotic ileum, compared to CD non-involved
tract and control ileum (Table 1), accompanied
by a severe disarrangement of wall architec-
ture, an high degree of fibrosis and a trans-
mural inflammation (inflammation score,  2-
3) that reached the muscularis propria. CD
non-involved tract showed a normal morpho-
logical pattern and a regular connective tissue
distribution, with a low level of inflammatory
infiltrate limited to the mucosa (inflammation
score, 1) as control specimen (Figure 1). In the
stenotic tracts  a significant increase of
immunostaining of  a-SMA  was observed
compared to normal and CD non involved
tracts where a-SMA expression was limited to
the smooth muscle cells of the muscularis
mucosa and the muscularis propria as well as
to the myocytes of the median layer of the ves-
sels (Figure 2). In stenotic lesions, a-SMA
immunoreactivity was also present in the
mucosa and submucosa. 
TGF-β expression (Figure 3I) was mild in
the submucosa and absent in the other wall
layers in control ileum. Its immunoreactivity
became mild in the muscularis propria in CD
non-involved tract. In CD stenotic tract TGF-β
staining was moderately expressed in the
mucosa,  severely widespread in the submu-
cosa and  moderately scattered in the smooth
muscle layers. PDGF expression (Figure 3II),
that was mild in the submucosa of control
ileum, showed a progressive marked increased
of immunopositivity throughout the mucosa,
submucosa and muscularis propria from con-
trol to CD stenotic samples. qPCR analysis of
the two growth factors was performed on cDNA
obtained from SMCs, isolated separately from
control, CD non-involved and stenotic tracts
(Figure 4). Control SMCs constitutively
expressed mRNA encoding for PDGF-β and
TGF-β. At the molecular level, TGF-β expres-
sion differed from immunohistochemical find-
ings in that it resulted highly expressed in
SMCs isolated from control ileum and progres-
sively decreased in CD non-involved and
stenotic tracts, reaching a statistically signifi-
cant difference in the latter in respect to con-
trol ileum (Figure 4A). Accordingly, a parallel
decrease in mRNA encoding for Trb3, one of
the key molecules for TGF-β signaling, was
observed, that resulted already statistically sig-
nificant in CD non-involved tract in respect to
control ileum. In turn, SMCs mRNA encoding
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Figure 1. Masson trichromic staining. In Control ileum (A) and in Crohn’s disease (CD)
non-involved tract (B) the inflammation was limited to the mucosa. CD stenotic tract (C)
showed a transmural inflammation that reached the submucosa (arrows) and the musco-
laris propria. Scale bars: 100 µm.
Table 1. Relative thickness of intestinal wall layers in control ileum, Crohn’s disease non-
involved and stenotic tracts.
Layers                                  Control        CD non-involved tract     Cd stenotic tract    P* 
Mucosa (µ)                                  384.84±12.10                  381.67±14.04                        661.75±70.72*       <0.005
Submucosa (µ)                           996.76±41.52                 1046.14±46.24                      1544.01±90.48*      <0.005
Muscolaris propria (µ)            1171.90±28.62                1191.06±36.76                      1779.07±87.44*      <0.005
Serosa (µ)                                   379.34±23.18                  389.49±30.46                        439.55±42.86*       =0.356
CD, Crohn’s disease. Data are expressed as mean± SEM of 3-6 experiments. *CD vs control.
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for PDGF-β paralleled  immunohistochemical
findings. PDGF-β was already significantly
over-expressed in SMCs isolated from CD non-
involved tract with respect to control ileum,
with a further increase in that isolated from
CD stenotic tract (Figure 4A). The progression
of PDGF-β expression was further evident
when qPCR products expression was compared
between the two CD tracts of the same patient,
with a 4.27±0.83 increase in SMCs isolated
from CD stenotic tracts (Figure 4B).
Colorimetric evaluation of collagen content
demonstrated statistically higher values of col-
lagen in the CD stenotic compared with CD
non-involved tracts (0.048±0.015 µg vs
0.034±0.006 µg, P<0.05), no significant differ-
ences were observed between CD non-involved
tract and control ileum (0.034±0.006 µg vs
0.032±0.007 µg, P=0.38). In addition, collagen
I-III immunoreactions, absent or mild in all the
layers of CD non-involved tract and control
ileum, resulted over-expressed  in CD stenotic
tract throughout all the intestinal layers,
except the serosa (Figure 5).  In parallel, SMCs
isolated from CD stenotic tract presented a sig-
nificant increase of 4.83±1.54 in mRNA encod-
ing for Collagen III expression towards CD
non-involved tract while no differences were
present between the latter and control ileum.
Further alterations in SMCs isolated from CD
tracts were observed in their morpho-functional
parameters, comparing to control (Table 2).
Firstly, SMCs presented a progressive shorten-
ing of resting cell length that reached a statis-
tical significance, with respect to control, in
SMCs isolated from CD stenotic tracts.
Secondly, SMCs presented an impairment of
maximal contractile response to the choliner-
gic agonist acethylcholine. In respect to con-
trol, maximal contraction to acetylcholine pro-
gressively decreased in SMC isolated from CD
non-involved ileum, reaching a statistical dif-
ference in SMCs isolated from CD stenotic
tracts. Finally, the neuronal cocktail
immunoreactivity in nerve cell bodies of the
myenteric plexus seems to show a disruption
of plexus in CD stenotic tracts, probably due to
an increase of the interspersed collagen fibers
(Figure 6, upper panels). No differences were
however observed in the percentage of the
area occupied by the plexus: 3.84±1.99 for CD
stenotic tract, 3.90±2.06 for CD non-involved
tract and 3.95±1.43 for control ileum.
Immunoreactivity of enteric glial cells (GFAP),
located in the myenteric plexus and in nerve
fibers of the circular and longitudinal muscle
layers, did not present differences between
control ileum and CD non-involved and stenot-
ic tracts (Figure 6, central panels). Conversely,
c-kit expression was confined at the level of
the myenteric plexus in CD non-involved tract
and  control ileum, while it was distributed
within the longitudinal and circular muscle
layers of the muscularis propria in CD stenotic
tract (Figure 6, lower panels).
Discussion
In the present study, the comparative analy-
sis carried out in parallel on whole mount tis-
sues and freshly isolated SMCs of the same CD
tracts, has offered the possibility to take a
snapshot of intrinsic myogenic alterations
occurring in vivo in chronic intestinal inflam-
mation. It was demonstrated that SMCs isolat-
ed from CD ileum presented an overexpression
of  PDGF-β, the main growth factor driving the
myogenic switch towards a synthetic pheno-
type, that was paralleled to a reduction of
mRNAs encoding for factors contributing to
the quiescent smooth muscle contractile phe-
notype, namely TGF-β and Trb3. Furthermore,
alterations in SMC morphology and contractile
activity were observed. These myogenic alter-
ations, similar to that observed in vascular
muscle,13,16 support the hypothesis that SMCs
concur to intestinal fibrogenesis. Interestingly,
these myogenic alterations were not only pres-
ent in stenotic tracts but were also found in
SMCs isolated from CD non-involved bowel.
This latter observation acquires a potential
importance in the context of the high recur-
rence post-surgical rate in the neoterminal
ileum immediately proximal to the anastomo-
sis.23,24
Fibrosis and CD stricture formation  is the
result of an uncontrolled and excessive process
of intestinal healing.  The main driver of gut
fibrogenesis appears to be chronic inflamma-
tion, which leads to intestinal mesenchymal
cell recruitment and activation. Up to now, evi-
dence indicates that inflammation induces the
activation of fibroblasts with increased biosyn-
thetic collagen activity. These collagen-produc-
ing fibroblasts are labeled with antibodies to
the filament aSMA supporting their differenti-
ation towards myofibroblasts. The increase in
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Table 2. Morpho-functional features of human smooth muscle cells isolated from control
ileum and Crohn’s disease (CD) non-involved and stenotic tracts. 
                                                         Control        CD non-involved tract   CD stenotic tract
Resting cell (µm)                                          93.45±2.91                      84.81±9.60                         67.84±3.32*
Acetylcholine-induced contraction (%)   19.20±2.57                      16.60±1.72                          8.14±1.14*
CD, Crohn’s disease. Data are expressed as mean± SEM of 3-6 experiments. *P<0.05 vs control.
Figure 2. Immunohistochemistry for a-Smooth Muscle Actin (a-SMA). A-C), a-SMA
immunoreactivity was limited to the muscolaris mucosa (arrows) and muscolaris propria
(*) in control ileum (A), Crohn’s disease non-involved (B), whereas in stenotic (C) (arrow
heads) tracts immunoreactivity was also present in mucosa and submucosa layers; scale
bars: 100 µm. D-F) a-SMA immunoreactivity in muscularis propria in control ileum (D),
Crohn’s disease non-involved (E) and stenotic (F) tracts; scale bars: 50 µm.
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the resident activated fibroblast population
represents a pivotal mechanism for the devel-
opment of intestinal fibrosis.25 However,
smooth muscle proliferation also affects the
nature and amount of extracellular matrix,
with an inflammatory milieu driving change to
these mesenchymal cells leading to fibrosis.
Increased muscle cell proliferation and hyper-
trophy has been reported in CD stenosis, driv-
en by an increase of Insulin-like growth factor-
I mRNA and IGF-I protein production.26
Besides, islands of SMCs in the submucosa,
with dense collagen deposition and disruption
and expansion of muscularis mucosa, as well
as collagen septae that extend through a disor-
ganized muscularis propria, to form a greatly
thickened muscularis, have been demonstrat-
ed in CD strictures.3 These alterations may
also lead to the presence of an additional mus-
cle layer in the submucosa with areas where a
fusion of the muscularis mucosae and propria
occurred.27 The overexpression of aSMA in all
wall layers  of CD stenotic tracts is in accor-
dance with the above observations  and sup-
ports the prevalent involvement of these two
aSMA-positive mesenchymal cells in CD stric-
ture,28 namely myofibroblasts and SMCs.
Whereas the origin of intestinal myofibrob-
lasts from fibroblasts has been established,
controversies exist about their possible origin
from SMCs. 
Protracted smooth muscle proliferation has
long been known to promote the loss of differ-
entiated smooth muscle characteristics29 and
TGF-β and the PDGF-β, key factors in the
intestinal myofibroblats fibrotic response,4
have been also demonstrated to regulate phe-
notypic SMCs plasticity. In proliferative and
obliterative vascular diseases, an aberrant
SMCs switch from contractile to synthetic phe-
notype occurs with their consequent prolifera-
tion and transformation into myofibrob-
lasts.13,30 Both growth factors, as well as colla-
gens, are synthesized by the same SMCs.31 In
vascular muscle, TGF-β stimulates the expres-
sion of contractile markers and maintains the
contractile phenotype14 whereas PDGF-β is
able to counteract the TGF signaling, through
downregulation of Smads, key pro-contractile
TGF-β-related signal transducers, and to medi-
ate a switch from a contractile to synthetic
phenotype, resulting in the de-differentiation
of vascular smooth muscle cells.16 These
inhibitory effects of PDGF-β on TGF-β signal-
ing are mediated by a small non-coding
microRNA (miRNA), namely miR-24. This
miRNA downregulates the expression of
Tribbles-like protein-3 (Trb3) mRNA with con-
sequent decrease in Smad protein levels and
then TGF-β signaling.32 Inhibition of miR-24
function in vascular smooth muscle prevents
the SMCs switch towards a synthetic pheno-
type upon PDGF treatment.33 The role of PDGF-
β in promoting growth of intestinal SMCs has
been recently studied.34 Pro-inflammatory
cytokines exerted a critical effect on SMCs by
stimulating the expression of PDGF receptor in
quiescent control cells and then further pro-
moting the resulting growth response through
its up-regulation. Immunohistochemical and
myogenic qPCR alterations observed in the
present study suggest that PDGF-β likely is
involved in human intestinal fibrosis.
Immunohistochemistry revealed a  progressive
overexpression from control ileum to CD
stenosis of PDGF-β in all wall layers and the
qPCR analysis highlighted  the intrinsic
increase in mRNA encoding for this growth
factor in SMCs isolated from CD ileum. In
muscle, this increase was paralleled by a
decrease in SMCs expressions of mRNA encod-
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Figure 3. Immunohistochemistry for TGF-β (I); A) TGF-β immunoreactivity was mild in
submucosa (arrow) in control ileum and (B) in Crohn’s disease non-involved, whereas in
stenotic (C) tracts TGF-β staining was moderately expressed in mucosa (arrow) and
severely widespread in submucosa (arrow heads); scale bars: 100 µm; D) TGF-β
immunoreactivity is absent in muscolaris propria in control ileum, mild in Crohn’s dis-
ease non-involved (E) and moderate scattered in stenotic (F) tracts; scale bars: 50 µm.
Immunohistochemistry for Platelet-Derived Growth Factor (PDGF) (II); A) PDGF
immunoreactivity was mild in submucosa (arrow) in control ileum; B) moderately
expressed in CD non-involved; C) markedly positive in stenotic tracts;  scale bars: 100
µm; D) PDGF immunolocalization in muscularis propria showed a progressive increase
of immunopositivity from in control ileum, Crohn’s disease non-involved (E) to stenotic
(F) tracts; scale bars: 50 µm.
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ing for TGF-β and Trb3. The intrinsic decrease
of TGF-β expression in freshly isolated SMCs
from CD tracts suggests that the moderate
scattered TGF-β immunopositivity of smooth
muscle layers might be ascribed to an attained
de-differentiation of SMC in myofibroblasts.
Available data on TGFβ expression in active
CD are controversial as some authors found
higher levels,35-37 while others found no differ-
ences compared to the healthy ileum.38,39 Of
note is that, among fibrogenetic parameters,
TGF-β mRNA expression is the only one that
differs depending on the diseased bowel side.38
Cellular mechanisms involved in SMCs
switch towards a synthetic de-differentiated
phenotype  appear then present in SMCs isolat-
ed from CD tracts suggesting, in accordance
with previous observations,40 a possible SMCs
involvement in stricture formation. Direct
assays of proteins are however required to
definitively establish smooth muscle contribu-
tion to CD fibrogenesis. In the light of the post-
surgery recurrent disease in the neoterminal
ileum, that maintains the original disease phe-
notype,41,42 the present demonstration of alter-
ations in mRNA expression, encoding for fac-
tors regulating pro-synthetic phenotype switch
already in SMCs isolated from CD non-involved
tract, acquires an important pathophysiological
relevance in the development of  new possible
therapeutic targets in anti-fibrotic treatments.
Besides hyperplasia and hypertrophy of
intestinal mesenchymal cells, the other main
feature of intestinal strictures is represented
by the thickening of all layers of the intestinal
wall  and the net increase in extracellular
matrix production and deposition3, both alter-
ations being observed in the present study.
Furthermore, similarly to the present observa-
tions, the increased levels of both type I and
type III collagens have already been reported in
CD fibrosis,43 mainly localized to internal
intestinal layers.44 Analysis of the collagen
types in human intestinal muscle reveals a
predominance of types I and III,27 the latter
subtype creates an ECM suited to scar contrac-
tion and stricture formation.45 An overexpres-
sion in mRNA encoding for collagen III was
observed in SMCs, that however, differently
from the previous parameters, was restricted
to cells isolated from CD stricture. These over-
all changes likely result in both a loss of the
normal compliance of the intestine and a
thickening of the intestinal wall, resulting ulti-
mately in the intestinal obstruction. Motor
alterations are also likely favored by the
observed changes of cellular SMCs morpholo-
gy, contractile activity and of the enteric nerv-
ous apparatus observed in CD tracts. Ileal gan-
glioneuritis and alterations in interstitial cells
of Cajal reported in CD ileum46 were in partly
also observed in CD strictures in the present
study. These were paralleled to differences in
the distribution of Cajal cells that were con-
fined to the myoenteric plexus in control
ileum, while interspersed within the muscle
layers in CD stenosis.
In conclusion, even if immunohistochemical
and molecular analyses cannot define the com-
plex relation between growth factors and intes-
tinal mesenchymal cells during initiation or
progression of fibrosis, this  study highlights
the presence of intrinsic myogenic alterations
that appear both in CD stricture and in the
upstream non-involved tract and that might
contribute to intestinal motor alterations and,
similarly to vascular musculature, might repre-
sent suitable possible new targets for anti-
fibrotic interventions.
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Figure 4. qPCR products expression analysis. A) Fold-variation from control ileum in the
expression of mRNA encoding for Platelet-derived growth factor (PDGF-β),
Transforming growth factor beta (TGF-β), Tribbles-like protein-3 (Trb3), Collagen I
(COLL I) and III (COLL III) in human smooth muscle cells isolated from Crohn’s dis-
ease non-involved (white column) and stenotic (grey column) tracts; data are mean ±SE
of 4 independent experiments; *P<0.05 vs control; #P<0.05 Crohn stenotic vs non-
involved tracts. B) %variation in expressions of mRNA encoding for Platelet-derived
growth factor (PDGF β), Transforming growth factor beta (TGF β), Tribbles-like pro-
tein-3 (trb3), Collagen I (COLL I) and III (COLLIII) in smooth muscle cells.
Figure 5. Immunohistochemistry for Collagen (I-III). A) Collagen (I-III) immunoreac-
tivity was absent or mild in mucosa and submucosa in control ileum; B) Crohn’s disease
non-involved; C) it was overexpressed in stenotic tracts (arrows); scale bars: 100 µm. D)
Collagen (I-III)  immunoreactivity located in muscolaris propria in control ileum; E) in
Crohn’s disease non-involved; F) stenotic tracts show the same trend observed in mucosa
and submucosa; scale bars: 50 µm.
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